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Advancing the defensive explanation for anxiety
disorders: lorazepam effects on human defense
are systematically modulated by personality
and threat-type
AM Perkins1, U Ettinger2, K Weaver3, A Schmechtig3, A Schrantee4, PD Morrison5, A Sapara6, V Kumari6, SCRWilliams3 and PJ Corr7
Clinically effective drugs against human anxiety and fear systematically alter the innate defensive behavior of rodents,
suggesting that in humans these emotions reflect defensive adaptations. Compelling experimental human evidence for this
theory is yet to be obtained. We report the clearest test to date by investigating the effects of 1 and 2mg of the anti-anxiety drug
lorazepam on the intensity of threat-avoidance behavior in 40 healthy adult volunteers (20 females). We found lorazepam
modulated the intensity of participants’ threat-avoidance behavior in a dose-dependent manner. However, the pattern of effects
depended upon two factors: type of threat-avoidance behavior and theoretically relevant measures of personality. In the case of
flight behavior (one-way active avoidance), lorazepam increased intensity in low scorers on the Fear Survey Schedule tissue-
damage fear but reduced it in high scorers. Conversely, in the case of risk-assessment behavior (two-way active avoidance),
lorazepam reduced intensity in low scorers on the Spielberger trait anxiety but increased it in high scorers. Anti-anxiety drugs do
not systematically affect rodent flight behavior; therefore, we interpret this new finding as suggesting that lorazepam has a
broader effect on defense in humans than in rodents, perhaps by modulating general perceptions of threat intensity.
The different patterning of lorazepam effects on the two behaviors implies that human perceptions of threat intensity are
nevertheless distributed across two different neural streams, which influence effects observed on one-way or two-way active
avoidance demanded by the situation.
Translational Psychiatry (2013) 3, e246; doi:10.1038/tp.2013.20; published online 16 April 2013
Introduction
Anxiety disorders are the most prevalent class of psychiatric
illness, affecting B60 million people per year in Europe
alone.1 Moreover, personality traits that reflect individual
differences in proneness to anxiety are an important risk factor
for psychiatric illness in general.2 Studies capable of explain-
ing the nature of anxiety, and why some people are especially
prone to it, are of fundamental importance in psychiatry. One
theory postulates that anxiety, as an evolved adaptation,
is a defensive reaction;3 and that anxiety disorders reflect
hyperactivity in brain systems that control defensive beha-
vior.4 Specifically, it has been argued that trait individual
differences in proneness to anxiety (phenotypic personality)
are caused by individual differences in sensitivity to threat.5
To date, experimental support for the defensive explanation
of anxiety disorders stem chiefly from ethopharmacological
studies showing that drugs with clinical effectiveness against
anxiety disorders in humans systematically alter the innate
defensive behavior of rodents.6 Concerns that rodent models
of psychological processes are too simple to apply to humans
demand validation evidence in humans.7 Neuroimaging
studies show that human brain systems, which govern
defensive behavior, also generate clinically important nega-
tive emotions,8–10 and a candidate genetic risk factor for panic
disorder hasbeen found to potentiate flight behavior.11However,
data more directly comparable to the cardinal rodent findings
are required, such as studies that systematically characterize
the effects of drugs with clinical effectiveness against anxiety
disorders on human defensive behavior.
To begin the ethopharmacological validation of the defen-
sive explanation for fear and anxiety in humans, we previously
tested the effects on intensity of threat-avoidance behavior of
two drugs used to treat anxiety disorders, namely lorazepam
(1mg) and citalopram (10mg).12On the basis of the defensive
direction theory, which associates anxiety and fear with
activity in parallel neural streams activated by approach
to threat and departure from threat, respectively,5,13 we
hypothesized that lorazepam (an anti-anxiety drug14) would
alter the intensity of behavior in response to threats requiring
approach (that is, two-way active avoidance). We also
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predicted that citalopram (an anti-panic drug15) would alter the
intensity of behavior in response to threats that need not be
approached (that is, one-way active avoidance). In 30 healthy
adult male humans, we found support for the former
hypothesis, as 1mg of lorazepammodulated risk-assessment
intensity (RAI), which we operationalized as the magnitude of
forward–backward oscillation during approach to threat
(an anxiety-related defensive behavior that is part of the
rodent risk-assessment response16) in a human analog of the
rodent paradigm, but 10mg citalopram exerted no significant
main effect on flight intensity (FI; a fear-related behavior in
rodents17). Here, we build on these previous findings by
testing the effects of two different doses of lorazepam (1 and
2mg) on one-way and two-way active avoidance in humans.
First, congruent with the theory that anxiety is elicited by
threats requiring approach and fear by threats that need not
be approached,5,13 we predicted that scores on a clinically
inspired questionnaire measure of anxiety-proneness (trait
anxiety) would correlate positively with RAI, whereas ques-
tionnaire scores on a clinically developed fear-proneness
scale (trait fear) would correlate positively with FI. We addi-
tionally predicted that scores on a general (super-ordinate)
measure of proneness to negative emotion (neuroticism)
would correlate positively with both RAI and FI. As all three of
these questionnaires gauge emotional dispositions, not
behavioral outputs, there is no a priori reason to expect a
positive correlation between any of their scores and the
intensity of threat-avoidance behavior unless such emotions
are, indeed, defensive in origin.
Second, anti-anxiety drug effects on rodent defensive
behavior are heterogeneous, with their patterning depending
upon the perceived level of threat in the situation: anti-anxiety
drugs reduce RAI in rodents exposed to mild threat, but
increase it in rodents exposed to severe threat.3 Extrapolating
these rodent data to humans, it has been proposed that
human (trait) personality differences are comparable to rodent
experimentally induced (state) differences.5,13 Thus, a human
scoring high on trait anxiety is viewed as analogous to a
severely threatened rodent, and vice versa. According to this
argument, lorazepam should increase risk-assessment beha-
vior in high-trait anxiety people, but decrease it in low-trait
anxious people. This theory predicts an interaction of trait
anxiety and lorazepam (the presence of a main drug effect
would depend on the exact form of this interaction).
In contrast, as anti-anxiety drugs do not systematically affect
rodent flight behavior,3 fear questionnaire scores should not
modulate lorazepam effects on human defensive responses
to threats that need not be approached (that is, FI). Finally,
lorazepam has sedative side effects;18 hence, we tested
whether effects of lorazepam on human defense are explic-
able as sedation confounds.
Participants and methods
Forty healthy volunteers (20 females; mean age 24.8 years,
s.d.±4.1) gave written informed consent as required by the
local ethics committee. Participants were medically screened
by telephone, and thosewho passedwere assessed in person
by a psychiatrist to ensure they were physically healthy and
had no current or past psychiatric disorders. After screening,
volunteers were familiarized with the experimental tasks and
then completed the Eysenck Personality Questionnaire–
Revised,19 Spielberger Trait Anxiety Inventory20 and the Fear
Survey Schedule (FSS).21 The first questionnaire was
administered, as its neuroticism scale provides a general
measure of proneness to negative emotion, scores on which
should hypothetically relate positively to both FI and RAI. The
last two questionnaires were administered in an attempt to
measure variance in specific emotional responses connected
to risk assessment and flight, respectively. More specifically,
clear a priori reasons exist to indicate that trait anxiety is the
best available index of individual differences in the reactivity of
brain systems that control the (complex) avoidance of threats,
but that require approach (for example, foraging in a field
with potential predators).5,13 We used the Tissue Damage
subscale of the FSS as a covariate for FI, as there are strong a
priori reasons for believing this construct is the best available
index of individual differences in the reactivity of brain systems
that control (simple) avoidance of threats that need not be
approached.11
We used a double-blind, placebo-controlled, randomized,
within-subjects design, comprising three experimental ses-
sions: placebo (50mg ascorbic acid), and 1mg and 2mg
lorazepam in a randomized order, and scheduled a week
apart to allow drug washout. Drugs were administered with
300ml of water and were contained in opaque capsules
so that the participants and experimenters were blind to the
experimental condition. After a 2-h wait for drug metabolism,
volunteers completed the experimental session that lasted
B40min.
The intensity of threat-avoidance behavior was indexed
using the JoystickOperatedRunway Task (JORT11), a human
translation of the Mouse Defense Test Battery (Figure 1a22),
which measures the one-way active avoidance (labeled FI
Figure 1b) and two-way active avoidance (labeled RAI;
Figure 1c) in response to threat of a 115-dB white noise
burst. To control for individual differences in the participants’
motor function and sedation effects of lorazepam, responses
were measured with and without threat, as signaled by the
presence or absence, respectively, of a lightning flash icon on
screen. In theMouse Defense Test Battery, escape speed is a
measure of rodent FI;23 in the human translation of the task,12
FI related to the degree to which threat (as signaled by the
lightning flash icon) increased the velocity of the green dot
cursor along the runway during one-way avoidance of the
red dot cursor, as shown in Figure 1b (that is, average velocity
in the one-way active avoidance trials that contained no
threat of white noise subtracted from the average velocity in
the one-way active avoidance trials with a threat of white
noise).
In the Mouse Defense Test Battery, approach-withdrawal
oscillation in the closed runway configuration is a component
of rodent risk-assessment behavior.16 In the same task,
approach-withdrawal oscillation has been linked to anxiety by
the finding that this behavior is sensitive to anxiolytic drugs.17
When the task was translated for human use,12 RAI was the
label chosen to describe the degree to which threat (as
signaled by the lightning flash icon) increased the magnitude
of forward–backward oscillation of the green dot when trapped
between the two red dot cursors (as shown in Figure 1c).12
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The face validity of the label of ‘RAI’ is limited, as in the human
version of the task the forward–backward oscillation serves no
information-gathering function. Nevertheless, to remain
consistent with the previously published research,12 the label
was retained in the present experiment with the proviso that
the forward–backward oscillation, labeled as risk assessment,
should be more strictly likened to the hesitant oscillation
behavior that has been noted for decades as a behavioral
marker of goal conflict in rodents, regardless of whether or not
it gathers information.5 RAI in the JORT was accordingly
calculated as standard deviation (s.d.) of the average velocity
(V) in the two-way active avoidance trials that contained no
threat (Ta) of white noise subtracted from s.d. of the average
velocity in the two-way active avoidance trials with threat (Tp)
of white noise. Thus, RAI¼V(s.d.).TaV(s.d.).Tp.
Each testing session consisted of 48 trials (12 of each of the
above types) presented in a pseudo-random order to enhance
unpredictability. To enhance further unpredictability, intertrial
intervals were varied pseudo-randomly between 15 and
30 s. To prevent prolonged exposure to white noise, a trial
terminated automatically as soon as the participant had
received a burst of white noise. If the participant successfully
avoided the threat stimuli for 7 s, the trial automatically
terminated.
To assess the effect of individual differences in how
aversive the participants found the JORT, a questionnaire
measure of state affect (the short-scale Positive Affect
and Negative Affect Schedule24) was administered immedi-
ately before and after the first completion of the task during
screening. Task aversiveness was calculated as PANAS
Negative score (post-task)PANAS Negative score (pre-task).
To dissociate putative effects of lorazepam on threat-
avoidance behavior from its sedative side effects,17 we also
measured its effects on prosaccade peak velocity using an
Eyelink 1000 eye-tracker (SR Research, Mississauga, ON,
Canada). This task indexes the speed to track a dot. It is a
sensitive and objective behavioral marker of the sedative
effects of benzodiazepines (the slower the eye movement,
the greater the sedation25,26), but does not expose
participants to threat.
Associations between dependent variables and scores on
trait anxiety and fear were assessed using Pearson’s
product–moment correlation coefficient (SPSS v.18.0, IBM
Corporation, Somers, NY, USA). Effects of drug upon the
intensity of threat-avoidance behavior were analyzed by
repeated measures analysis of covariances, in which drug
(placebo, and 1 and 2mg lorazepam) formed a three-level
within-subjects factor. As females tend to be significantly
Figure 1 (a) The Mouse Defense Test Battery (MDTB). (b, c) The human translation of the MDTB, the Joystick Operated Runway Task. A force-sensing joystick apparatus
(PH-JS1; Psyal, London, UK) controls the speed of a cursor (green dot) in an on-screen runway; the harder the joystick is pushed, the faster the cursor travels. In the one-way
active avoidance phase, this cursor was pursued by a single threat stimulus (red dot; b). Participants received an unpleasant but harmless 115-dB white noise burst of near
instantaneous rise time lasting 250ms if the red dot collided with the green dot. The two-way active avoidance phase (c) was identical, except that a second red dot travelled
ahead of the green dot at a constant velocity, causing a goal conflict whereby the participant had to travel fast enough to avoid the pursuing threat, but not so fast that they
collided with the leading threat stimulus.
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more vulnerable than males to anxiety disorders,27,1 partici-
pant sex was entered into the analysis of covariances as a
between-subjects factor. The personality variables predicted
to be important by the defensive direction theory (trait anxiety
and tissue-damage fear) were entered as covariates in the
analysis of covariances of RAI and flight intensity, respect-
ively. Simple contrasts were used to test for the specific
direction of drug effects against placebo.
Results
Personality effects on task performance. Table 1 shows
means, s.d. and intercorrelations of individual differences
and performance variables. In terms of correlations with
defensive behavior, bivariate correlations showed that
whereas trait anxiety and tissue damage were both signifi-
cantly related to FI in placebo, only trait anxiety was signifi-
cantly correlated with risk assessment intensity in the 2 mg
condition. FSS tissue-damage fear was the only personality
questionnaire variable that showed a statistically significant
positive correlation with ratings of task aversiveness.
Drug effects on task performance. When drug effects on
task performance were analyzed without taking into account
personality effects, there were no significant main effects
of lorazepam on FI or RAI: F (2, 38)¼ 0.1, P¼ 0.922,
np
2
¼ 0.002; F (2, 38)¼ 0.1, P¼ 0.903, np
2
¼ 0.003. Nor were
there any significant drug sex interactions for FI and RAI:
F (2, 38)¼ 0.3, P¼ 0.744, np
2
¼ 0.002; F (2, 38)¼ 0.5,
P¼ 0.638, np
2
¼ 0.012. However, when personality variables
were included in the analysis as covariates, significant
modulating effects of the drug on defensive behavior were
found.
With regard to RAI, the main effect of lorazepam reached
trend level significance, F (2, 36)¼ 2.5, P¼ 0.086,
np
2
¼ 0.064, as did the drug by trait anxiety interaction,
F (2, 36)¼ 2.5, P¼ 0.089, np
2
¼ 0.063. However, simple
contrasts revealed that for the placebo versus 2mg
lorazepam condition, there was a significant effect of
drug, F (1, 39)¼ 4.3, P¼ 0.045, np
2
¼ 0.105, and also a
significant interaction between lorazepam and trait anxiety
questionnaire scores:F (1, 39)¼ 4.2,P¼ 0.049, np
2
¼ 0.101. In
the placebo versus 1mg condition, there were no significant
effects of drug, F (1, 39)¼ 0.2, P¼ 0.642, np
2
¼ 0.006 or of
drug with trait anxiety, F (1, 39)¼ 0.1, P¼ 0.710, np
2
¼ 0.004.
Figure 2b illustrates this interaction by dividing the sample
along the median on trait anxiety, showing that RAI was
reduced by 2mg lorazepam in low scorers on trait anxiety but
was increased in high scorers on trait anxiety. There was no
significant interaction between drug condition and participant
sex, F (2, 74)¼ 0.5, P¼ 0.595, np
2
¼ 0.014, nor was there a
significant interaction between subjects effects on RAI of
participant sex, F (1, 37)¼ 0.0, P¼ 0.971, np
2
¼ 0.000, or trait
anxiety, F (1, 37)¼ 1.5, P¼ 0.222, np
2
¼ 0.040.
Contrary to expectations, lorazepam altered FI, showing a
significant main effect of drug condition, F (2, 36)¼ 5.4,
P¼ 0.006, np
2
¼ 0.127, no significant interaction between
drug condition and participant sex, F (2, 36)¼ 0.6,
P¼ 0.539, np
2
¼ 0.017, but a significant interaction between
drug condition and scores on FSS tissue-damage fear,
F (2, 36)¼ 6.4, P¼ 0.003, np
2
¼ 0.148. Figure 2a reveals that
lorazepam decreased FI in participants in the upper half of the
sample on tissue-damage fear (that is, the particularly threat-
sensitive participants) but increased it in the lower half of the
sample (that is, the particularly threat-insensitive partici-
pants). This outcome was confirmed by simple contrasts
between placebo and 2mg lorazepam: F (1, 39)¼ 8.6,
P¼ 0.006, np
2
¼ 0.189. The contrast for placebo versus
1mg failed to reach significance: F (1, 39)¼ 2.6, P¼ 0.110,
np
2
¼ 0.068. A similar pattern emerged for the simple contrasts
for the interaction of drug with FSS tissue-damage fear
(placebo versus 1mg: F (1, 39)¼ 3.5, P¼ 0.068, np
2
¼ 0.068;
placebo versus 2mg F (1, 39)¼ 10.2, P¼ 0.003, np
2
¼ 0.216.
There was also a main effect of sex, indicating that FI was
significantly higher in females than males, irrespective of drug
condition or personality questionnaire scores, F (1, 37)¼ 5.0,
P¼ 0.031, np
2
¼ 0.119. The between subjects effect of FSS
tissue-damage fear on FI failed to reach significance,
F (1, 37)¼ 2.3, P¼ 0.134, np
2
¼ 0.060.
Drug effects on prosaccade peak velocity. Repeated
measures analysis of variance showed a large and sig-
nificant main effect of drug condition on prosaccade peak
velocity, F (2, 37)¼ 28.1, Po0.001, np
2
¼ 0.425, with simple
contrasts revealing that, as expected, lorazepam
reduced prosaccade peak velocity in a dose-dependent
manner: placebo versus 1mg: F (1, 38)¼ 21.4, Po0.001,
np
2
¼ 0.360; placebo versus 2mg; F (1, 38)¼ 43.2, Po0.001,
Table 1 Means, s.d. and intercorrelations of individual differences variables
Variable Mean (s.d.) 1 2 3 4 5 6 7 8 9 10 11
1. Trait anxiety 35.78 (9.19) —
2. Tissue-damage fear 19.30 (11.45) 0.344* —
3. Social fear 29.65 (20.09) 0.607** 0.666** —
4. Neuroticism 9.15 (7.18) 0.825** 0.258 0.529** —
5. Task aversiveness 0.45 (2.26) 0.083 0.376* 0.117 0.084 —
6. Flight intensity (placebo) 0.21 (0.48) 0.374* 0.421** 0.220 0.314* 0.212 —
7. Flight intensity (1mg lorazepam) 0.21 (0.35) 0.147 0.133 0.335* 0.313* 0.212 0.192 — -
8. Flight intensity (2mg lorazepam) 0.24 (0.39)  0.163 0.263  0.288 0.139 0.119  0.191 0.074 —
9. Risk assessment intensity (placebo) 0.04 (0.11)  0.080 0.172 0.201 0.010 0.133  0.179 0.134  0.177 —
10. Risk assessment intensity (1mg lorazepam) 0.03 (0.12) 0.013 0.152 0.121 0.188 0.047 0.003 0.073 0.023 0.034 —
11. Risk assessment intensity (2mg lorazepam) 0.03 (0.17) 0.318* 0.217 0.209 0.239 0.025 0.093 0.067  0.152 0.025  0.051 —
N¼40 (20 male). Correlations reflect Pearson’s product–moment correlation coefficients. *Po0.05; **Po0.01.
Lorazepam effects on human defense
AM Perkins et al
4
Translational Psychiatry
np
2
¼ 0.532. Table 2 shows correlations between the changes
(that is, drug score–placebo score) induced by lorazepam in
prosaccade peak velocity and the changes induced by
lorazepam in the JORT variables of FI and risk assessment.
There were no significant correlations between these two
forms of lorazepam effects, indicating that the sedative effect
of lorazepam was not responsible for altering the defensive
behavior of participants.
Discussion
We found two forms of support for the general hypothesis
that anxiety-related illness is caused by alterations in the
functioning of brain systems that control defensive beha-
viour.3 First, scores on clinically relevant questionnaire
measures of fear and anxiety proneness were positively
correlated with the intensity of flight and risk-assessment
behavior, respectively (Table 1). Second, these questionnaire
scores differentially modulated the effects of lorazepam on
these two defensive behaviors.
The patterning of the interactive drug and personality
effects on defensive behavior was complex, but those
pertaining to RAI conformed to the predictions of the
defensive direction theory.5,13 This theory associates anxiety
with threats that require approach and fear with threats that
need not be approached. This theory postulates that these
two threat types are processed by two parallel defensive
systems. The theory maintains that trait individual differences
in the reactivity of the two systems influence an individual’s
personality profile. More specifically, it has been predicted
that individuals with particularly high levels of reactivity in
the systems controlling responses to threats that require
approach theoretically should display high scores on trait
anxiety.13
This is important in the present context, as the theory likens
individual differences in human-trait anxiety to state differ-
ences in threat exposure in rodents, and these rodent-state
differences modulate anti-anxiety drug effects (anti-anxiety
drugs reduce RAI in rodents exposed to mild threat, but
increase it in rodents exposed to severe threat).3 If this aspect
of the defensive direction theory is correct, in humans
lorazepam should hypothetically dampen RAI in low scorers
on trait anxiety, but potentiate RAI in high scorers on trait
anxiety. As Figure 2b shows, this is what we found, although
only for 2mg lorazepam, suggesting that 1mg was not a
sufficiently large dose to cause systematic changes in risk
assessment.
As shown in Figure 2a, effects of personality/lorazepam
modulation were also found on FI. These effects are not
readily explicable by the defensive direction theory, which
aligns fear with flight, and hence predicts that lorazepam, as
an anti-anxiety drug, should not affect FI. Nevertheless, the
effects are clear: FI was reduced in a dose-dependentmanner
by lorazepam in high scorers on tissue-damage fear, but it
was increased in a dose-dependent manner in low scorers on
this scale.
Although this result differs from rodent findings, it is readily
explicable in terms of the difference in the human analog of the
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Figure 2 (a) Flight intensity (FI) was significantly decreased by lorazepam in participants with high levels of threat magnification, as indexed by the tissue-damage
subscale of the Fear Survey Schedule (FSS), but FI was increased in low FSS scorers. (b) Risk assessment intensity (RAI) was significantly higher in participants scoring
above the median on Trait Anxiety (error bars represent one s.e.m.; *Po0.05, **Po0.01). It should be noted that the division of the groups into high–low scorers was purely
for illustrative purposes; the analysis of covariance was conducted using questionnaires as continuous variables.
Table 2 Means, s.d. and intercorrelations of changes to defensive behavior and eye movements induced by lorazepam
Variable Mean (s.d.) 1 2 3 4 5 6
1. Change in prosaccade peak velocity (1mg lorazepam–placebo)  25.35 (34.13) —
2. Change in prosaccade peak velocity (2mg lorazepam–placebo)  41.65 (39.59) 0.677** —
3. Change in flight intensity (1mg lorazepam–placebo) 0.02 (0.54) 0.053 0.253 —
4. Change in flight intensity (2mg lorazepam–placebo) 0.03 (0.67) 0.023 0.183 0.677** —
5. Change in risk assessment intensity (1mg lorazepam–placebo)  0.01 (0.16) 0.149  0.216  0.134 0.009 —
6. Change in risk assessment intensity (2mg lorazepam–placebo)  .0.01 (0.20) 0.029  0.057  0.169 0.146 0.309 —
N¼40 (20 male). Correlations reflect Pearson’s product–moment correlation coefficients *Po0.05; **Po0.01.
Lorazepam effects on human defense
AM Perkins et al
5
Translational Psychiatry
rodent defensive situation; in relation to human defensive
behavior, the context is important.28 In this context, there is a
difference in knowledge between rodent and human subjects
in experimental defensive situations. Whereas rodents are
threat-naive before the task onset,3 our participants knew that
the task entailed punishment. Thus, the entire testing session
is, in effect, an approach-to-threat situation that, according to
the defensive direction theory, should elicit anxiety and thus
should show lorazepam effects on flight behavior. This
interpretation has the merit of fitting with a theory that
sustained apprehension, such as occurs in a 20-min long
punishment-related testing session of the type experienced by
our participants, is related to anxiety rather than fear.29
As regards the different patterning of effects of lorazepam
and personality questionnaire scores on FI and RAI (Figures
2a and b), a viable, if tentative, explanation draws upon a
supplementary postulate of the defensive direction theory,
namely that within both fear- and anxiety-related neural
streams, mild threats activate the upper levels, whereas
severe/immediate threats activate the lower levels.13 As
rodent studies indicate that anti-anxiety drugs reduce the
perceived intensity of threat,30 this facet of the defensive
direction theory implies that lorazepam should affect activity in
both neural streams. The notion that lorazepam modulates
perceptions of intensity of threats in general is backed up in
humans by a variety of other studies, such as the finding that
anti-anxiety benzodiazepine drugs reduce fear/anxiety-poten-
tiated startle, but have no effect on baseline startle31,32 or on
pleasure-attenuated startle.33 However, based on our new
data, we suggest the particular neural stream activated
depends upon the trial type of the joystick task: the differences
seen in lorazepam effects on FI and RAI (Figures 2a and b)
provide circumstantial evidence for the effects of two such
neural streams. This a highly theoretical conjecture, but at this
early stage of understanding the neural control of human
defence we hope even tentative theoretical links, such as
those identified here, may provide guidance for subsequent
more detailed research efforts.
Ultimately, it may be the case that our results are best
explained by a combination of the two arguments we have
outlined. At themild levels of general threat experienced when
the participant enters the testing chamber, it seems likely that
forebrain-mediated anxiety roughly equivalent to sustained
apprehension will predominate. Then, once the task is
underway and threat levels peak, lower levels of the neural
streams come online that are more sharply differentiated
according to whether the threat stimulus must be approached.
Thus, we tentatively suggest that, in humans the upper
(mild threat) levels of the two neural streams are merged in
favor of anxiety by the sheer generality of mild threat
situations. However, once threats become more immediate,
then the lower, more situationally specific levels of the neural
streams become active, giving rise to the different patterning
of lorazepam effects seen in flight and risk assessment. This
explanation is consistent with the significant comorbidity seen
among anxiety and fear disorders.34
The above explanation is reinforced by our finding of
theoretically congruent personality effects on the two types of
defensive behavior. In the case of flight behavior, lorazepam
increased intensity in low scorers on FSS tissue-damage fear
but reduced it in high scorers. In the case of risk assessment,
lorazepam reduced intensity in low scorers on the Spielberger
trait anxiety but increased it in high scorers. The validity of this
latter result is supported by its conformity with our previous
finding12 of a tendency for lorazepam to reduce RAI in low
scorers on FSS social fear.
Individual differences in the general perception of threat
intensity have been aligned with scores on the major
personality dimension of neuroticism.5 This dimension is
found in all of the leading descriptive models of personality
and reflects individual differences in proneness to negative
emotions of all kinds,35,36 whether abstract or situationally
elicited. In the Eysenck Personality Questionnaire–Revised
neuroticism scale, the questions do not reference specific
situations, but instead are phrased in abstract terms such as
‘Does your mood often go up and down?,’ ‘Do you ever feel
‘just miserable’ for no reason?’ or ‘Would you call yourself a
nervous person?.’ In the light of our results, it is plausible that
these questions index the effects of the merged upper levels
of the fear and anxiety systems. Specifically, as most threats
actually encountered in everyday life are mild, comorbidity of
anxiety disorders37 might be explained by this combined
effect, which itself is related to the fact that negative emotions
in humans are usually of an anxiety nature. In contrast, it might
be the case that the dedicated questionnaire measures of
fear- and anxiety proneness that modulated lorazepam
effects (Figures 2a and b) are indexing individual differences
in reactivity, specifically at lower levels of the neural streams,
but that these lower levels of the defensive system are only
activated relatively infrequently in everyday life.
Finally, interpretation of our results may be informed by
some highly tentative attempts to align them with certain key
findings pertaining to panic and anxiety. First, although
lorazepam is primarily viewed as an anti-anxiety drug, it has
been found to have clinically significant anti-panic effects at
doses approximately double of those at which it shows
anti-anxiety effects (for example, 7mg per day).38–40 There-
fore, it is possible that the capacity of lorazepam to alter FI in
the JORT reflects high sensitivity of the JORT to this anti-
panic effect; future research could explore this possibility by
testing participants on the JORT using higher doses of
lorazepam, providing they did not become so sedated as to
be unable to manipulate the joystick effectively. Furthermore,
there is evidence that relieving anxiety can induce panic.41
This phenomenon is typically explained by the association of
anxiety with the activation of forebrain structures that process
responses to mild, complex or abstract threats. These
structures are thought to inhibit activity in midbrain structures
that control flight behavior and mediate panic in response to
close, intense, concrete threats.42 Thus, one effect of an anti-
anxiety drug, such as lorazepam, is to reduce inhibitory power
of the forebrain, freeing the midbrain to unleash panic-based
flight behavior. The boosting effect of lorazepam on FI in low
scorers on tissue damage fear might tentatively be explained
as reflecting this releasing effect, on the basis that some of the
variance captured by this questionnaire may reflect individual
differences in forebrain inhibition. This may mean that low
scorers on tissue-damage fear, having relatively little fore-
brain inhibition, are more easily pushed into intense, panic-
related flight from threat by the releasing effects of lorazepam
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than high scorers, even though tissue-damage fear scores are
positively correlated with flight in the placebo condition
(Table 1, Figure 2a).
Turning to the effects of lorazepam on RAI (Figure 2b) and
links to the general construct of neuroticism, rodent studies
show that benzodiazepine drugs have a greater conflict-
reducing effect on nonemotional rats compared with
emotional rats.43,44 The two strains of rats were bred for
differences in the number of fecal boluses deposited
during 2min in the open-field test.45 Rodents innately seek
dark, sheltered, quiet areas, as these offer protection from
predators, and hence the brightly lit, noisy open-field arena is
highly aversive to the average rat; the number of fecal boluses
produced was viewed as a marker of fear. Subsequently, it
has been found that the emotional rats show greater
responses on a whole range of other negative and conflict-
related tasks46 and this has led to rats from the emotional
strain being viewed as roughly analogous to a human with a
highly anxiety-prone, neurotic personality.5 In the light
of this analogy, our finding that 2mg lorazepam significantly
reduced conflict-related behavior (RAI) in low scorers
on trait anxiety, yet boosted it in high scorers, would seem
to be broadly consistent with findings on the effects
of benzodiazepine drugs on emotional versus non-emo-
tional rats, if we accept that trait anxiety and neuroticism are
closely related in psychometric terms (correlated 0.825,
Table 1).
In conclusion, we associate defensive behavior with the
clinically important negative emotions of anxiety and fear,
consistent with the hypothesis that anxiety disorders can be
explained as reflecting changes in the functioning of defensive
brain systems.3 Our findings also show a partial fit with the
defensive direction theory5,13 that aligns fear with departure
from threat and anxiety with approach to threat; trait anxiety
questionnaire scores were positively associated with RAI
during approach to threat, and fear questionnaire scores were
associated with flight behavior. Contrary to expectations, we
found the anti-anxiety drug lorazepam affected both forms of
behavior, but showed a differing pattern of effects on risk
assessment and flight, suggesting that the defensive behavior
of our participants reflected a combination of fear and anxiety
activation. We speculate that initial impressions of threat
elicited by the testing scenariomay be processed at amerged,
higher neural level, but that during the task separable neural
streams governing anxiety-mediated risk assessment or fear-
mediated simple avoidance also come into play, depending
upon whether the threat stimulus requires approach.
Our data additionally shed light on the basis of human
personality more generally, as we also found a significant
positive association between FI and questionnaire scores on
neuroticism. This latter result agrees with the notion that
individual differences in sensitivity to threat contribute
variance to neuroticism5 and has broad relevance, as it
allows our human defense findings to be fitted directly into the
standard rubric of personality research.
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